EP0384130A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Myocardial infarction immunoassay
Assignee: International Immunoassay Laboratories Inc
•
Filing: 1990-01-22
•
Granted: —
•
Expires: 2010-01-22
Abstract
Abstract Methods and reagents for determining the lapse of time since an acute disease event, such as the occurrence of a myocardial infarction, are presented. A serum or plasma sample is assayed to determine the concentration of two analyte sets. From these measurements, the time of the acute event can be more accurately determined. Novel antibodies, labeled and insolubilized derivatives of these antibodies, labeled proteins, and kits containing one or more of these reagents are also described.
Inventors
- 👤 Vipin D. Shah
- 👤 Shing-Erh Yen
- 👤 Gerald M. Anchin
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 17:36
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/0004; C12N9/0006; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K16/00; C07K16/18; C07K16/40; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/573; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S436/815
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
154 words
An immunological method for determining the lapse of time since an acute biological episode in a patient comprising (a) determining the concentration in a serum or plasma sample of a first analyte set comprising at least one substance selected from a transiently elevated substance, an endogenously altered form of said transiently elevated substance, and combinations thereof; (b) determining the concentration in the sample of a second analyte set comprising at least one substance selected from a transiently elevated substance, an endogenously altered form of said transiently elevated substance, and combinations thereof; wherein at least one of the analyte sets includes a transiently elevated substance and the first and the second analyte sets are not the same; and (c) determining the ratio of the first and the second analyte sets wherein the ratio of the first and second analyte sets provides an indication of the lapse of time since the occurence of the acute episode.
Claim 2
Dependent Claim
154 words
An immunological method for determining the lapse of time since an acute biological episode in a patient comprising (a) determining the concentration in a serum or plasma sample of a first analyte set comprising at least one substance selected from a transiently elevated substance, an endogenously altered form of said transiently elevated substance, and combinations thereof; (b) determining the concentration in the sample of a second analyte set comprising at least one substance selected from a transiently elevated substance, an endogenously altered form of said transiently elevated substance, and combinations thereof; wherein at least one of the analyte sets includes a transiently elevated substance and the first and the second analyte sets are not the same; and (c) determining the ratio of the first and the second analyte sets wherein the ratio of the first and second analyte sets provides an indication of the lapse of time since the occurence of the acute episode.
Claim 3
Dependent Claim
41 words
A method according to Claim 1 wherein each of the first and second analyte sets are selected from CK-MM A , CK-MM B CK-MM C , CK-MB A , CK-MB B , MI-P A , MI-D B , and combinations thereof.
Claim 4
Dependent Claim
26 words
A method according to Claim 1 or 2 wherein the transiently elevated substance in each of the first and second analyte sets are not the same.
Claim 5
Independent Claim
117 words
A method of any one of Claims 1 to 3 wherein the first and second analyte sets are selected from: (a) one analyte set is MI-P A and the other analyte set is MI-D B ; (b) one analyte set is CK-MM A+B+C and the other analyte set is CK-MM C ; (c) one analyte set is CK-MM A+B and the other analyte set is CK-MM C ; (d) one analyte set is CK-MB A+B and the other analyte set is CK-MB B ; (e) one analyte set is CK-MB A+B and the other analyte set is CK-MB A ; and (f) one analyte set is CK-MB A and the other analyte set is CK-MB B .
Claim 6
Independent Claim
20 words
A method according to any one of Claims 1 to 4 wherein the acute biological episode is a myocardial infarction.
Claim 7
Dependent Claim
5 words
An anti-(MI-P A ) antibody.
Claim 8
Dependent Claim
5 words
An anti-(MI-P A ) antibody.
Claim 9
Dependent Claim
5 words
An anti-(MI-D B ) antibody.
Claim 10
Dependent Claim
5 words
An anti-(MI-D B ) antibody.
Claim 11
Dependent Claim
7 words
A hybridoma having accession number ATCC HB9913.
Claim 12
Dependent Claim
7 words
A hybridoma having accession number ATCC HB9913.
Claim 13
Dependent Claim
7 words
A hybridoma having accession number ATCC HB99l2.
Claim 14
Dependent Claim
7 words
A hybridoma having accession number ATCC HB99l2.
Claim 15
Dependent Claim
7 words
A hybridoma having accession number ATCC HB9914.
Claim 16
Dependent Claim
7 words
A hybridoma having accession number ATCC HB9914.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.